Characteristics of patients with COVID-19 receiving CAR T-cell therapy (n = 30)
| Patient . | Baseline hematological malignancy . | Disease status at COVID-19 diagnosis . | Time from CAR T cells to COVID-19, d . | CAR T-cell construct . | Bridging therapy . | Lymphodepletion . | Grade at CAR T-cell therapy . | CRS/ICANS treatment . | Reason for death (time after COVID-19 diagnosis, d)* . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CRS . | ICANS . | Tocilizumab . | Steroids . | ||||||||
| 1 | NHL LBCL | R/R | 37 | Axi-cel | X | Flu-Cyc | 1 | 1 | Malignancy (35) | ||
| 2 | NHL LBCL | CR | 221 | Axi-cel | X | Flu-Cyc | 1 | NA | NA | ||
| 3 | NHL LBCL | CR | 240 | Axi-cel | Flu-Cyc | 2 | NA | X | X | COVID-19 + other (52) | |
| 4 | NHL LBCL | R/R | 1 | Tisa-cel | X | Flu-Cyc | 2 | NA | X | X | COVID-19 (25) |
| 5 | NHL LBCL | CR | 85 | Axi-cel | Flu-Cyc | 1 | 2 | X | NA | ||
| 6 | NHL LBCL | SD | 14 | Tisa-cel | X | Benda | 2 | 1 | X | X | COVID-19 + other (170) |
| 7 | MM | R/R | 90 | BCMA ARI-0002 | X | Flu-Cyc | NA | NA | NA | ||
| 8 | NHL LBCL | R/R | 42 | Tisa-cel | X | Flu-Cyc | 2 | NA | X | X | Malignancy + COVID-19 (33) |
| 9 | NHL LBCL | R/R | 397 | Tisa-cel | X | Flu-Cyc | 2 | NA | X | NA | |
| 10 | NHL LBCL | CR | 313 | Axi-cel | X | Flu-Cyc | 1 | NA | X | NA | |
| 11 | ALL | Unknown | 9 | Tisa-cel | Flu-Cyc | NA | NA | NA | |||
| 12 | NHL LBCL | R/R | 302 | Axi-cel | X | Flu-Cyc | 1 | NA | X | COVID-19 (42) | |
| 13 | NHL LBCL | CR | 95 | Tisa-cel | X | Flu-Cyc | NA | NA | NA | ||
| 14 | NHL LBCL | CR | 457 | Axi-cel | X | Flu-Cyc | 1 | NA | NA | ||
| 15 | NHL LBCL | R/R | 158 | Axi-cel | X | Flu-Cyc | 1 | NA | X | X | Malignancy (22) |
| 16 | NHL LBCL | R/R | 65 | Tisa-cel | X | Flu-Cyc | 1 | 3 | X | X | Malignancy + COVID-19 (21) |
| 17 | NHL LBCL | CR | 270 | Axi-cel | X | Flu-Cyc | 3 | NA | X | X | NA |
| 18 | NHL LBCL | Unknown | 19 | Tisa-cel | Flu-Cyc | 2 | NA | X | COVID-19 (50) | ||
| 19 | NHL LBCL | R/R | 180 | Tisa-cel | Flu-Cyc | 1 | NA | X | X | NA | |
| 20 | NHL LBCL | CR | 186 | Tisa-cel | Flu-Cyc | 1 | NA | COVID-19 (51) | |||
| 21 | NHL LBCL | CR | 348 | Axi-cel | Flu-Cyc | 2 | 2 | X | X | NA | |
| 22 | NHL LBCL | CR | 19 | Tisa-cel | X | Flu-Cyc | 1 | NA | NA | ||
| 23 | NHL LBCL | CR | 605 | Tisa-cel | X | Flu-Cyc | NA | NA | COVID-19 (46) | ||
| 24 | NHL NOS | CR | 635 | Axi-cel | Flu-Cyc | 1 | NA | COVID-19 (44) | |||
| 25 | NHL LBCL | R/R | 180 | Tisa-cel | X | Flu-Cyc | 1 | NA | Malignancy + COVID-19 (32) | ||
| 26 | NHL LBCL | CR | 485 | Axi-cel | X | Flu-Cyc | 1 | NA | COVID-19 (53) | ||
| 27 | NHL LBCL | CR | 510 | Axi-cel | Flu-Cyc | 1 | NA | COVID-19 (124) | |||
| 28 | NHL LBCL | CR | 66 | Tisa-cel | X | Flu-Cyc | 1 | NA | X | NA | |
| 29 | NHL LBCL | R/R | 12 | Tisa-cel | X | Flu-Cyc | 1 | 1 | NA | ||
| 30 | NHL LBCL | CR | 35 | Tisa-cel | X | Flu-Cyc | NA | NA | NA | ||
| Patient . | Baseline hematological malignancy . | Disease status at COVID-19 diagnosis . | Time from CAR T cells to COVID-19, d . | CAR T-cell construct . | Bridging therapy . | Lymphodepletion . | Grade at CAR T-cell therapy . | CRS/ICANS treatment . | Reason for death (time after COVID-19 diagnosis, d)* . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CRS . | ICANS . | Tocilizumab . | Steroids . | ||||||||
| 1 | NHL LBCL | R/R | 37 | Axi-cel | X | Flu-Cyc | 1 | 1 | Malignancy (35) | ||
| 2 | NHL LBCL | CR | 221 | Axi-cel | X | Flu-Cyc | 1 | NA | NA | ||
| 3 | NHL LBCL | CR | 240 | Axi-cel | Flu-Cyc | 2 | NA | X | X | COVID-19 + other (52) | |
| 4 | NHL LBCL | R/R | 1 | Tisa-cel | X | Flu-Cyc | 2 | NA | X | X | COVID-19 (25) |
| 5 | NHL LBCL | CR | 85 | Axi-cel | Flu-Cyc | 1 | 2 | X | NA | ||
| 6 | NHL LBCL | SD | 14 | Tisa-cel | X | Benda | 2 | 1 | X | X | COVID-19 + other (170) |
| 7 | MM | R/R | 90 | BCMA ARI-0002 | X | Flu-Cyc | NA | NA | NA | ||
| 8 | NHL LBCL | R/R | 42 | Tisa-cel | X | Flu-Cyc | 2 | NA | X | X | Malignancy + COVID-19 (33) |
| 9 | NHL LBCL | R/R | 397 | Tisa-cel | X | Flu-Cyc | 2 | NA | X | NA | |
| 10 | NHL LBCL | CR | 313 | Axi-cel | X | Flu-Cyc | 1 | NA | X | NA | |
| 11 | ALL | Unknown | 9 | Tisa-cel | Flu-Cyc | NA | NA | NA | |||
| 12 | NHL LBCL | R/R | 302 | Axi-cel | X | Flu-Cyc | 1 | NA | X | COVID-19 (42) | |
| 13 | NHL LBCL | CR | 95 | Tisa-cel | X | Flu-Cyc | NA | NA | NA | ||
| 14 | NHL LBCL | CR | 457 | Axi-cel | X | Flu-Cyc | 1 | NA | NA | ||
| 15 | NHL LBCL | R/R | 158 | Axi-cel | X | Flu-Cyc | 1 | NA | X | X | Malignancy (22) |
| 16 | NHL LBCL | R/R | 65 | Tisa-cel | X | Flu-Cyc | 1 | 3 | X | X | Malignancy + COVID-19 (21) |
| 17 | NHL LBCL | CR | 270 | Axi-cel | X | Flu-Cyc | 3 | NA | X | X | NA |
| 18 | NHL LBCL | Unknown | 19 | Tisa-cel | Flu-Cyc | 2 | NA | X | COVID-19 (50) | ||
| 19 | NHL LBCL | R/R | 180 | Tisa-cel | Flu-Cyc | 1 | NA | X | X | NA | |
| 20 | NHL LBCL | CR | 186 | Tisa-cel | Flu-Cyc | 1 | NA | COVID-19 (51) | |||
| 21 | NHL LBCL | CR | 348 | Axi-cel | Flu-Cyc | 2 | 2 | X | X | NA | |
| 22 | NHL LBCL | CR | 19 | Tisa-cel | X | Flu-Cyc | 1 | NA | NA | ||
| 23 | NHL LBCL | CR | 605 | Tisa-cel | X | Flu-Cyc | NA | NA | COVID-19 (46) | ||
| 24 | NHL NOS | CR | 635 | Axi-cel | Flu-Cyc | 1 | NA | COVID-19 (44) | |||
| 25 | NHL LBCL | R/R | 180 | Tisa-cel | X | Flu-Cyc | 1 | NA | Malignancy + COVID-19 (32) | ||
| 26 | NHL LBCL | CR | 485 | Axi-cel | X | Flu-Cyc | 1 | NA | COVID-19 (53) | ||
| 27 | NHL LBCL | CR | 510 | Axi-cel | Flu-Cyc | 1 | NA | COVID-19 (124) | |||
| 28 | NHL LBCL | CR | 66 | Tisa-cel | X | Flu-Cyc | 1 | NA | X | NA | |
| 29 | NHL LBCL | R/R | 12 | Tisa-cel | X | Flu-Cyc | 1 | 1 | NA | ||
| 30 | NHL LBCL | CR | 35 | Tisa-cel | X | Flu-Cyc | NA | NA | NA | ||
Other reasons for death: Patient #3, possible IFI; patient #6, pulmonary embolism and heart failure.
ALL, acute lymphoblastic leukemia; axi-cel, axicabtagene ciloleucel; BCMA, B-cell maturation antigen; benda, bendamustine; CR, complete remission; CRS, cytokine release syndrome; Flu-Cyc, fludarabine plus cyclophosphamide; ICANS, immune effector cell-associated neurotoxicity syndrome; LBCL, large B-cell lymphoma; MM, multiple myeloma; NA, not applicable; NHL, non-Hodgkin lymphoma; R/R, relapsed/refractory; SD, stable disease; tisa-cel, tisagenlecleucel.
Other reasons for death: patient 3, possible invasive fungal infection; patient 6, pulmonary embolism and heart failure.